Alfa Institute of Biomedical Sciences, 9 Neapoleos Street, 151 23 Marousi, Athens, Greece.
Int J Antimicrob Agents. 2011 Apr;37(4):283-90. doi: 10.1016/j.ijantimicag.2010.11.032.
Prulifloxacin is a fluoroquinolone antibiotic that has been approved in several European countries for the treatment of lower urinary tract infections and exacerbations of chronic bronchitis. In this review, PubMed and Scopus databases were searched for potential uses of prulifloxacin beyond respiratory and urinary tract infections. Nine individual articles (eight randomised controlled trials and one cohort study) were regarded as eligible for inclusion in the review. Three of the studies were double-blinded, whilst six were open-label trials. Three studies referred to the treatment of patients with chronic bacterial prostatitis (CBP), one to prophylaxis of patients undergoing transrectal prostate biopsy, one to prophylaxis of women undergoing surgical abortion, two to patients with traveller's diarrhoea, one to diabetic patients with soft tissue infections or osteomyelitis, and one to improving tolerance of Bacillus Calmette-Guérin (BCG) instillations in patients with bladder cancer. Regarding CBP, prulifloxacin was non-inferior to its comparators, with a trend towards better microbiological outcomes at follow-up. Regarding traveller's diarrhoea, prulifloxacin resulted in better clinical and microbiological outcomes compared with placebo. Finally, prulifloxacin decreased the adverse events associated with BCG instillations in patients with bladder cancer, without affecting cancer recurrence rates. In summary, prulifloxacin appears to be a promising agent for the treatment of bacterial prostatitis and traveller's diarrhoea.
普卢利沙星是一种氟喹诺酮类抗生素，已在多个欧洲国家获得批准，用于治疗下尿路感染和慢性支气管炎急性发作。在本次综述中，我们在 PubMed 和 Scopus 数据库中检索了普卢利沙星在呼吸道和尿路感染以外的潜在用途。有 9 篇单独的文章（8 项随机对照试验和 1 项队列研究）被认为符合纳入标准。其中 3 项研究为双盲，6 项为开放性试验。有 3 项研究涉及慢性细菌性前列腺炎（CBP）患者的治疗，1 项涉及经直肠前列腺活检患者的预防，1 项涉及手术流产妇女的预防，2 项涉及旅行者腹泻患者，1 项涉及糖尿病合并软组织感染或骨髓炎患者，1 项涉及提高膀胱癌患者卡介苗（BCG）灌注的耐受性。关于 CBP，普卢利沙星与对照药物相比不劣效，随访时微生物学疗效有改善趋势。关于旅行者腹泻，普卢利沙星与安慰剂相比，临床和微生物学疗效更好。最后，普卢利沙星降低了膀胱癌患者接受 BCG 灌注时的不良反应，而不影响癌症复发率。总之，普卢利沙星似乎是治疗细菌性前列腺炎和旅行者腹泻的一种很有前途的药物。
